Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma”

48 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 48 results

Early research (Phase 1)UnknownNCT05315830
What this trial is testing

HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Who this might be right for
Adenocarcinoma - GEJAdenocarcinoma of the Stomach
The First Affiliated Hospital of Bengbu Medical University 10
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Early research (Phase 1)Ended earlyNCT01705340
What this trial is testing

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05190445
What this trial is testing

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Who this might be right for
HER2-positive Gastric Cancer
Pieris Pharmaceuticals, Inc. 80
Testing effectiveness (Phase 2)Looking for participantsNCT06423885
What this trial is testing

BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd. 40
Testing effectiveness (Phase 2)Study completedNCT04014075
What this trial is testing

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Who this might be right for
Adenocarcinoma Gastric Stage IV With MetastasesAdenocarcinoma - GEJ
Daiichi Sankyo 79
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07327229
What this trial is testing

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited 132
Large-scale testing (Phase 3)Ended earlyNCT01641939
What this trial is testing

Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 415
Large-scale testing (Phase 3)Looking for participantsNCT06901531
What this trial is testing

Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Not applicableStudy completedNCT05892926
What this trial is testing

HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia

Who this might be right for
Adenocarcinoma
AstraZeneca 204
Not applicableAvailableNCT06048081
What this trial is testing

Early Access Program for Zolbetuximab

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma CancerLocally Advanced Unresectable Gastric Adenocarcinoma CancerMetastatic Gastric Adenocarcinoma Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Study completedNCT02795988
What this trial is testing

IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

Who this might be right for
Gastrointestinal NeoplasmsAdenocarcinoma
Imugene Limited 64
Not applicableLooking for participantsNCT05993234
What this trial is testing

Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Who this might be right for
HER2-positive Advanced Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 257
Testing effectiveness (Phase 2)Looking for participantsNCT07025889
What this trial is testing

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Who this might be right for
Gastric Cancer
Ruijin Hospital 55
Testing effectiveness (Phase 2)Looking for participantsNCT06023758
What this trial is testing

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

Who this might be right for
HER2-positive Locally Advanced Resectable Gastric Cancer
Peking University 18
Testing effectiveness (Phase 2)Looking for participantsNCT05715931
What this trial is testing

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Who this might be right for
Adenocarcinoma of the StomachAdenocarcinoma of Esophagogastric JunctionHER2-positive Gastric Cancer
Yu jiren 30
Testing effectiveness (Phase 2)Study completedNCT01472029
What this trial is testing

Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the Stomach
AIO-Studien-gGmbH 53
Testing effectiveness (Phase 2)Study completedNCT01364493
What this trial is testing

Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Peking University 51
Testing effectiveness (Phase 2)UnknownNCT05218148
What this trial is testing

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Who this might be right for
HER2-positiveLocally Advanced Solid TumorImmunotherapy+4 more
Aiping Zhou 44
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507
What this trial is testing

Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Load More Results
500
507